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Abstract
Background: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions
worldwide. Identification of clinical and biological markers (“biomarkers”) of treatment response could personalize
clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery
study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration
Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that
help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of
this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological,
molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in
MDD.
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Methods: CAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with
other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line
antidepressant (escitalopram 10–20 mg/d) that, if clinically warranted after eight weeks, is augmented with an
evidence-based, add-on medication (aripiprazole 2–10 mg/d). Comprehensive datasets are obtained using clinical
rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic,
genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance
imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics
platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and
machine-learning techniques to identify predictors, moderators, and mediators of treatment response.
Discussion: From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD and 49 healthy
participants) has been evaluated at baseline. The clinical characteristics of this cohort are similar to other studies of MDD.
Recruitment at all sites is ongoing to a target sample of 290 participants. CAN-BIND will identify biomarkers of treatment
response in MDD through extensive clinical, molecular, and imaging assessments, in order to improve treatment practice
and clinical outcomes. It will also create an innovative, robust platform and database for future research.
Trial registration: ClinicalTrials.gov identifier NCT01655706. Registered July 27, 2012.
Background
Depressive disorders, including Major Depressive
Disorder (MDD), are highly prevalent and disabling
conditions with substantial personal and societal
costs [1]. MDD is now the second leading cause of
disability worldwide [2] and contributes to excess
mortality associated with many comorbid medical
conditions [3]. Treatment of depressive disorders is
based on empirical data and evidence-based guide-
lines, but treatment selection remains more of an art
than a science. Hence, the discovery of clinical and
biological markers, or biomarkers, of treatment re-
sponse that would inform an individualized approach
to depression treatment remains a research goal [4].
A major challenge to identify predictors (baseline
characteristics that predict response), moderators (base-
line characteristics that predict differential response to a
specific treatment) and mediators (events or changes oc-
curring during treatment that explains the response) is
that MDD is a complex, heterogeneous condition. A var-
iety of neurobiological and environmental influences,
both independently and in combination with one an-
other, can alter the clinical expression of MDD in terms
of symptoms, severity, episode duration, response to
treatment, and functional outcomes. As a result, no
single intervention is effective for all people with de-
pression. Current diagnostic systems such as the
DSM-5 [5] can reliably codify depressive symptoms as
criteria for MDD, but these symptoms are not unique
to depression and, even if clustered together, may not
represent a specific underlying disease process or a
treatment substrate. Hence, the clinical entity termed
“Major Depressive Disorder” represents only the final,
external manifestations of an enormously complex,
multi-level, multi-factorial process.
The Canadian Biomarker Integration Network in De-
pression (CAN-BIND) [6] was created with an aim to
use an integrated approach to biomarker discovery.
CAN-BIND draws on multidisciplinary expertise from
investigative teams at 8 Canadian universities, all in ac-
tive collaboration with the Ontario Brain Institute (OBI)
[7] and Indoc Research (Toronto, ON, Canada). The
Canadian Institutes of Health Research, academic insti-
tutions, and various industry partners provide additional
funding and support (see Acknowledgements).
The overall goal of CAN-BIND is to identify predictors,
moderators, and mediators of treatment response and
non-response in people with MDD to guide clinical
decision-making. CAN-BIND-1 uses an integrated clinical,
neuroimaging and molecular approach with high-di-
mensional mathematical modeling techniques to specific-
ally search for (a) baseline predictors and moderators of
antidepressant and adjunctive agent response, (b) early
treatment mediators of response (changes from baseline
to 2 weeks), and (c) later treatment mediators of response
(changes from baseline to 8 weeks, and to 16 weeks).
Methods
Overview of protocol
Patients with MDD are treated with open-label escitalo-
pram 10–20 mg/d for 8 weeks. Responders (≥50 % re-
duction in Montgomery-Åsberg Depression Rating Scale
[MADRS] score) continue on escitalopram for another
8 weeks, while non-responders have aripiprazole 2–
10 mg/d added on to escitalopram for 8 weeks. Clinical,
neuroimaging and molecular assessments are conducted
at Baseline (Week 0) and Weeks 2 and 8; clinical and mo-
lecular assessments also are conducted at Weeks 4, 10,
and 16; and additional brief clinical evaluations are com-
pleted at Weeks 6, 12, and 14. Clinical characterization
Lam et al. BMC Psychiatry  (2016) 16:105 Page 2 of 13
assesses a broad palette of symptoms, functional out-
comes, cognitive performance, personality dimensions,
and recent and past life events.
Participants
Participants are recruited at 6 clinical centres: Vancouver
(Djavad Mowafaghian Centre for Brain Health), Calgary
(Hotchkiss Brain Institute), Toronto (2 sites: University
Health Network and Centre for Addiction and Mental
Health), Hamilton (St. Joseph’s Healthcare Hamilton),
and Kingston (Providence Care, Mental Health Services).
Research Ethics Boards at each site approved the study.
Recruitment draws upon outpatient-referral networks,
community-based advertising, and dedicated knowledge
translation (KT) activities.
Table 1 lists the inclusion and exclusion criteria for
the patients with MDD. Healthy comparison participants
are 18–60 years of age, with no psychiatric or unstable
medical diagnosis, and sufficient fluency in English to
complete study procedures. They are matched to the pa-
tient group by sex and age distribution.
Procedure
At the Screening Visit, eligible participants provide writ-
ten, informed consent for all study procedures. Each pa-
tient undergoes screening evaluations that include a full
psychiatric consultation to confirm a diagnosis of MDD
using the Mini International Neuropsychiatric Interview
(MINI) [8]. Previous medication history (type, dose, and
duration) is collected using the Antidepressant Treat-
ment History Form (ATHF) [9]. A detailed medical his-
tory and listing of concomitant treatments, if any, are
recorded. A reproductive/menstrual history is obtained
from female patients. Patients undergo medical work-up
that includes physical examination, height and body
weight measurements, clinical laboratory assays, and 12-
lead electrocardiography (if indicated). Social back-
ground is collected using standardized reporting forms
for demographic characteristics, handedness, ethnicity,
education (expressed as years of formal schooling), mari-
tal status, occupational status, job classification, and
household income. Participants are screened for contra-
indications to magnetic resonance imaging (MRI).
Figure 1 shows an overview of the protocol. At the
Baseline Visit (Visit 1, Week 0), extensive clinical assess-
ments are conducted, and blood and urine samples are
obtained for molecular analysis. Participants also
undergo the first of 3 sessions of structural and func-
tional neuroimaging and electroencephalography (EEG),
as described below. All patients start treatment with
escitalopram and receive standardized clinical manage-
ment based on the CANMAT clinical guidelines [10].
Neuroimaging/EEG, molecular and clinical assessments
are conducted again at Weeks 2 and 8. Additional blood
samples are collected at Week 4 for pharmacogenetic ana-
lysis, and at Weeks 2, 10, and 16 for medication levels.
Blood chemistry screening, urinalysis, and body weight
measurements are repeated at Week 16. At the conclusion
of the study, patients are discharged into standard clinical
care by a family physician and/or regular psychiatrist. Pa-
tients can also elect to enrol in a long-term naturalistic
follow-up study that includes wellness monitoring using
electronic mental health (e-Mental Health) tools.
Healthy comparison participants attend 5 study visits:
Screening, Baseline, Week 2, Week 8, and Week 16.
They complete the same assessments as patients but do
not receive any treatment.
Treatments
In Phase 1, patients receive flexibly dosed escitalopram
(10–20 mg/d) for 8 weeks. Patients are started at 10 mg/d
Table 1 Inclusion and exclusion criteria for patients
Inclusion Criteria
• Outpatients 18 to 60 years of age.
• DSM-IV-TR criteria for MDE in MDD, as confirmed by the MINI.
• Depressive episode duration ≥3 months.
• Free of psychotropic medications for at least 5 half-lives (i.e. 1 week
for most antidepressants, 5 weeks for fluoxetine) before baseline.
• Score ≥24 on the MADRS.
• Fluent in English, sufficient to complete the interviews and
self-report questionnaires.
Exclusion Criteria
• Diagnosis of Bipolar I or Bipolar II disorder.
• Any other psychiatric diagnosis that is considered the primary diagnosis.
• Any significant personality disorder diagnosis (e.g., borderline,
antisocial) that might interfere with participation in the protocol,
defined by clinician judgment.
• High suicidal risk, defined by clinician judgment.
• Substance dependence/abuse in the past 6 months.
• Significant neurological disorders, head trauma, or other unstable
medical conditions.
• Pregnant or breastfeeding.
• Psychosis in the current episode.
• High risk for hypomanic switch (i.e., history of antidepressant-
induced hypomania).
• Failed 4 or more adequate pharmacologic interventions
(as determined by the ATHF).
• Previously failed or showed intolerance to escitalopram or
aripiprazole.
• Started psychological treatment within the past 3 months with the
intent of continuing treatment.
• Contraindications to MRI.
DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision; MDE, Major Depressive Episode; MDD, Major Depressive
Disorder; MINI, Mini International Neuropsychiatric Interview; MADRS,
Montgomery-Åsberg Depression Rating Scale; ATHF, Antidepressant Treatment
History Form
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and increased to 20 mg/d at Week 2 if they do not achieve
≥20 % reduction in MADRS score from baseline, and at
Week 4 for those who do not achieve ≥50 % reduction in
MADRS.
In Phase 2, patients who achieve ≥50 % reduction in
baseline MADRS score at Week 8 are considered “re-
sponders” and continue on their effective dose of escita-
lopram for a further 8 weeks. Patients who do not
achieve ≥50 % reduction in MADRS are considered
“non-responders” and receive flexibly dosed aripiprazole
(2–10 mg/d), added to escitalopram, for a further
8 weeks. Dose increases of aripiprazole are recom-
mended if patients do not achieve ≥50 % reduction in
MADRS after 2 or 4 weeks.
This standardized algorithm reflects usual clinical
practice, is consistent with evidence-based treatment
guidelines [11–13], and promotes consistency across all
sites. Doses can be decreased at the discretion of the
treating psychiatrist if patients do not tolerate higher
doses. Treatment is open-label, and no randomization
procedures are used. Medication adherence is monitored
with pill counts at each visit.
Concomitant non-psychotropic medications for stable
conditions are allowed at the discretion of the study
psychiatrist, who can also permit use of vitamins, supple-
ments, oral contraceptives, and non-prescription analge-
sics. Patients on pre-existing stable doses are allowed to
continue on zopiclone up to 7.5 mg prn or lorazepam
1–2 mg prn, to a maximum of 3 doses/week.
Assessments
Clinical platform
The clinical assessments (Table 2) are selected based on
theoretical and clinical utility and to minimize respondent
burden as much as possible. Raters received training, and
inter-rater reliability was established using recorded inter-
views. Clinician-rated symptom and clinical measures in-
clude the Montgomery-Asberg Depression Rating Scale
(MADRS), using the structured interview guide (SIGMA)
to enhance reliability [14, 15], and Clinical Global Impres-
sion, Severity and Improvement scales (CGI-S and CGI-I)
[16]. Depressive and other associated symptoms are ex-
plored in greater detail using the Depression Inventory
Development (DID) semi-structured interview, as part of
the International Society for CNS Drug Development’s ini-
tiative to refine and validate a new measurement tool for
use in clinical trials of MDD [17]. Patient-rated symptom
scales include the Quick Inventory for Depressive Symp-
tomatology (QIDS-SR) [18] and the Generalized Anxiety
Disorder (GAD-7) scale [19]. Manic and hypomanic
symptoms are assessed with the clinician-rated Young
Mania Rating Scale (YMRS) [20] and the patient-rated
Hypomania Check-List (HCL-32) [21].
Self-rated scales are used to assess functional impairment
(Sheehan Disability Scale; SDS) [22] and occupational func-
tioning (Lam Employment Absence and Productivity Scale;
LEAPS) [23]. Quality of life is measured both generally
(World Health Organization Quality of Life Assessment;
WHOQoL-BREF) [24] and with a specific focus on depres-
sion (Quality of Life, Enjoyment and Satisfaction Question-
naire; Q-LES-Q) [25], using these 2 self-rated measures.
We also assessed other behavioural and dimensional
constructs, including aversive and incentive motivation
(Behavioural Inhibition System/Behavioural Activation
System; BIS/BAS) [26], anhedonia (Dimensional Anhedonia
Rating Scale; DARS; and Snaith-Hamilton Pleasure Scale;
SHAPS) [27, 28], personality (NEO Five-Factor Inventory;
NEO-FFI) [29] and pain (Brief Pain Inventory; BPI-SF) [30].
Fig. 1 CAN-BIND-1 Clinical Protocol
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Sleep, circadian rhythms, and seasonality are assessed using
the Pittsburgh Sleep Quality Index (PSQI) [31], the Biological
Rhythms Interview of Assessment in Neuropsychiatry
(BRIAN) [32], and the Seasonal Pattern Assessment Ques-
tionnaire (SPAQ) [33]. Physical activity is measured using
the self-rated International Physical Activity Questionnaire
(IPAQ) [34], while dietary habits are assessed through a
series of brief questions.
Assessment of environmental stressors includes adult pat-
terns of attachment and recent stressful life events that are
captured with self-report scales, including the Experience in
Close Relationships (ECR-R) [35] scale, and the List of
Threatening Experiences (LTE) [36], respectively.
Two clinical interviews are conducted by centralized,
trained raters at Queen’s University and facilitated by Medeo,
a secure telehealth/videohealth service (Medeo, Vancouver,
BC, Canada). The Childhood Experience of Care and Abuse
(CECA) [37], administered at Week 4 to patients and at
Week 2 to healthy participants, is a semi-structured inter-
view that carefully assesses childhood maltreatment. The Life
Events and Difficulties Schedule (LEDS) [38], administered
at Week 16 to all participants, is a semi-structured context-
ual interview and rating system that assesses stressful life
events that have occurred within 6 months of depression on-
set. Interviews are audiotaped and transcribed so that re-
sponses can be coded based on standard, manualized
conventions.
CNS Vital Signs (CNS VS) is a computerized test battery
used to assess memory, reaction time and psychomotor
speed, complex attention, and cognitive flexibility [39]. The
reliability of CNS VS is similar to that of conventional neuro-
psychological tests [40]. The CNS VS has a robust normative
database and is sensitive to common causes of cognitive im-
pairment. Analyses of cognitive data will be augmented with
an estimate of premorbid intelligence obtained using the Na-
tional Adult Reading Test (NART) [41].
Medication side effects are documented with the
clinician-rated Toronto Side Effects Scale (TSES) [42],
which records the incidence, frequency, and severity of
common adverse events, and the Sexual Functioning
Questionnaire (SexFX), which evaluates specific sexual
functioning [43]. Adverse Events are classified as mild,
moderate or severe.
Neuroimaging platform
fMRI Structural and functional neuroimaging data are ob-
tained on 3.0 Tesla (3 T) magnetic resonance imaging (MRI)
systems using multicoll phased-array head coils. Among the
6 clinical sites, 4 different models of scanners are used, thus
mandating an extensive and ongoing standardization and
quality control process to ensure that data are comparable
and usable [44]. The four models of scanners include Discov-
ery MR750 3.0T (GE Healthcare, Little Chalfont, Bucking-
hamshire, UK), Signa HDxt 3.0T (GE Healthcare, Little
Chalfont, Buckinghamshire, UK), MAGNETOM TrioTim
(Siemens Healthcare, Erlangen, Germany), and Achieva 3.0T
(Philips Healthcare, Best, Netherlands). Cross-site T1 piloting
included a “human phantom”, who travelled to each site for
anatomical scans, and a manganese chloride (MnCl2)-based
phantom model for progressive quantitative assessment of
hydration based on signal intensity linearity characteristics
[45]. Since the study’s launch, each site has obtained monthly
scans of 2 geometric phantoms (a spherical agar phantom
developed by the Function Bioinformatics Research Net-
work, and a custom-built cylindrical model using plastic
LEGO blocks) [46, 47] to facilitate scanner calibration and
troubleshooting over the long term.
Table 2 Clinical characterization assessments
Clinician-Administered Assessments
Montgomery Asberg Depression Rating Scale (MADRS)
Young Mania Rating Scale (YMRS)
Clinical Global Impression (CGI)
Depression Inventory Development (DID) Interview
Toronto Side Effects Scale (TSES)
Sexual Side Effects Questionnaire (SexFX)
Childhood Experience of Care and Abuse (CECA)
Life Events and Difficulties Schedule (LEDS)
CNS Vital Signs (CNS-VS) computerized neuropsychological test battery
National Adult Reading Test (NART)
Self-Report Assessments
Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR)
Generalized Anxiety Disorder 7-item scale (GAD-7)
Hypomania Check-List (HCL-32)
Brief Pain Inventory (BPI)
Sheehan Disability Scale (SDS)
Lam Employment Absence and Productivity Scale (LEAPS)
Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
World Health Organization Quality of Life Assessment (WHOQoL-BREF)
Pittsburgh Sleep Quality Index (PSQI)
Seasonal Pattern Assessment Questionnaire (SPAQ)
Biological Rhythm Interview of Assessment in Neuropsychiatry (BRIAN)
Dimensional Anhedonia Rating Scale (DARS)
Snaith-Hamilton Pleasure Scale (SHAPS)
Behavioural Inhibition/Behavioural Activation System (BIS/BAS)
NEO Five-Factor Inventory (NEO-FFI)
Experiences in Close Relationships (ECR-R) questionnaire
List of Threatening Experiences (LTE)
International Physical Activity Questionnaire (IPAQ)
Brief Diet Questionnaire
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Following surveys and localization, the examination
protocol includes a whole-brain T1-weighted turbo gradi-
ent echo sequence (9 min) at 1 mm3 resolution, repetition
time (TR) = 6.2–1900 ms, echo time (TE) = 2.7–3.5 ms, flip
angle = 8–15°, inversion time (TI) = 0–1100 ms, field of
view (FOV) = 220–256 mm, matrix 2562–5122, 170–180
contiguous slices at 1 mm thickness. A small Vitamin E
capsule is placed as a stereotactic marker at the right tem-
ple to confirm subject orientation during image review [48].
Secondly, a whole-brain diffusion tensor imaging (DTI)
series is obtained using 30 gradient directions at 2 b-values
(500 and 1000 s/mm2) (5 min) with an additional 3 im-
ages at b = 0 s/mm2 for tensor construction at a final
voxel resolution of 2.3 x 2.3 x 5 mm (1 min). Func-
tional MRI includes a 10-min resting state scan with
eyes open using a fixation cross [49], obtained using
a whole-brain T2*-sensitive blood oxygenation level-
dependent (BOLD) echo planar imaging (EPI) series.
At the inception of the study, a BOLD EPI series was used
during the Emotional Face Categorization/Conflict Task (2
runs of 7 min each) [50, 51]. After enrolling a cohort of 107
patients and 52 healthy participants, we substituted a reward
paradigm and an implicit go no-go task. These tasks allow
for the assessment of reward networks and attentional biases
for affectively laden stimuli [52]. The substitution, rather
than addition, of the functional tasks was necessary to main-
tain a feasible total time for participants in the scanner. The
new tasks involve a 12-min hedonic function task [53, 54],
where participants receive feedback and earn small monetary
rewards while choosing correct responses among sets of vis-
ual stimuli and a 10-min affective go/no-go task to a series
of stimuli that contain emotional content [55]. Stimulus
sizes, instructions to participants, and support materials are
standardized across sites. All behavioural data are captured
using E-Prime software version 2.0 or higher (Psychology
Software Tools, Sharpsburg, PA, USA).
Electroencephalography The fMRI tasks were trans-
lated into analogous versions for electroencephalography
(EEG), which is carried out at 4 sites, again using several
equipment models (Biosemi ActiveTwo [BioSemi, Amsterdam,
Netherlands], BrainVision Recorder/QuickAmp [Brain Prod-
ucts, Munich, Germany], Compumedics NeuroScan [Compu-
medics USA, Charlotte, NC, USA] , EGI Geodesic [Electrical
Geodesics, Eugene, OR, USA]) that require cross-site consult-
ation and standardization. All sites used a minimum of 64-
channel caps and conductive electrode gels, with 53 common
electrodes identified across the different systems. EEGs are digi-
tized continuously (bandpass 0.04–100 Hz with 1000 Hz sam-
pling rate) and all electrodes are referenced to the vertex
(Cz) electrode.
At each session, participants complete a 10-min fixation
resting state sequence with eyes open, followed by a 10-min
resting state sequence with eyes closed. As with fMRI, the
Emotional Face Categorization/Conflict Task was used for
EEG when the study began, but was later changed to a task
querying anhedonia in MDD and an affective go/no-go task,
also using E-Prime software. Ocular artifacts, such as blinks,
saccades, and lateral movements, are removed by independ-
ent component analysis (ICA) as implemented in EEGLAB
[56] and performed using MATLAB (MathWorks, Natick,
MA, USA).
Molecular platform
Blood and urine samples for genomic and proteomic analyses
are collected from all participants at Weeks 0, 2, 8 and 16.
Following blood draws at Weeks 0, 2, and 8, total RNA is im-
mediately isolated from leukocytes and stabilized using the
LeukoLOCK filter apparatus (Thermo Fisher Scientific, Wal-
tham, MA, USA), which also depletes globin mRNA to im-
prove the utility of samples for expression profiling and other
applications. For patients with MDD, additional blood sam-
ples are collected at Week 4 for pharmacogenetic analysis
and at Weeks 2, 10, and 16 for drug levels.
Standard Operating Procedures (SOPs) for sample re-
ceipt and accessioning, nucleic acid extraction, quality as-
sessment, data tracking, DNA and RNA preparation for
assays, scanning, and feature extraction are in place.
Objectives of the molecular platform are to investigate
1) candidate biomarkers for disease state or drug response
in baseline samples in patients and healthy participants, 2)
global DNA alterations that may correlate with disease
state or drug response using baseline samples, and 3) dy-
namic molecules in pre- and post- treatment samples to
identify pathways of drug response and select additional
targets for investigation by targeted methods.
De-identified specimens are transferred to and stored
at the Douglas Mental Health University Institute biore-
pository in accordance with regulatory guidelines and
best practices for biobanking. A subset of samples is
transferred to other CAN-BIND sites for specific ana-
lyses. Material transfer agreements between sites were
established at the outset of the study.
Targeted analyses include DNA single-nucleotide poly-
morphism (SNP) open-array analysis to identify and se-
quence variants that correlate with disease state or drug
response [57], along with studies using established
methods for profiling of mRNA and miRNA sequences,
histone modifications, and methylation status across the
genome [58]. Proteomic analysis by selected-reaction
monitoring mass spectrometry (SRM-MS) with state-of-
the-art hybrid triple quadrupole/linear ion trap liquid-
chromatography mass spectrometry (5500 and 4000
QTRAPs), will be used for relative quantification of
high-interest plasma proteins within biological pathways
with purported relationships to MDD [59].
Exploratory analyses include RNA-Seq for miRNA from
blood and from plasma using either a HiSeq (Illumina,
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San Diego, CA, USA) or Proton (Thermo Fisher Scientific,
Waltham, MA, USA) platform. DNA oxidative damage to
guanine will be evaluated by measuring levels of 8-hydroxy-
2-deoxyguanosine (8-OhdG) using a competitive ELISA ana-
lysis kit (StressMarq BioSciences, Victoria, BC, Canada).
Cytosine oxidation will be measured using an ELISA-based
assay to assess the levels of 5-hydroxymethylcytosine
(MethylFlash™Methylated DNA Quantification Kit; Epi-
gentek Group, Farmingdale, NY, USA). Global DNA
methylation (i.e., 5-methylcytosine) will be evaluated
using an ELISA-based method (Sigma-Aldrich, Darm-
stadt, Germany). Inflammatory markers in blood will be
measured using standard antibody-based immunoassays.
Data management
Each site has entered a standardized Participation Agree-
ment with OBI to facilitate transfer of both raw and
processed/de-identified data, in accordance with OBI’s Gov-
ernance Policy and with any specific conditions required by
each institution’s local legislative and/or ethical policies.
De-identified electronic data from all sites are aggregated
for data analyses using multiple bioinformatics approaches.
The OBI’s Centre for Ontario Data Exploration (“Brain-
CODE”, https://www.braincode.ca/) is an online neuroin-
formatics platform that allows researchers to collaborate
across distances and work more efficiently, and ultimately,
to promote new discoveries to improve patient care. Brain-
CODE provides the rare capability of supporting scientific
inquiry and analytics across multiple brain diseases and
modalities by integrating clinical, imaging, pathology, and
genomics data. Standard variable definitions and formats
are used so that investigators collect data consistently
across studies and modalities. This will reduce variability in
data collection and facilitate comparisons across diseases,
merging of data sets and meta-analyses.
In storing sensitive patient information, Brain-CODE
employs sophisticated security systems and utilizes Priv-
acy by Design (PbD) to protect privacy by embedding it
into the design specifications of technologies, business
practices, and physical infrastructure [7]. The OBI also
works with several research ethics boards and related or-
ganizations to streamline the project review and ap-
proval process; and develops opportunities to link or
integrate Brain-CODE with other provincial, national, or
international databases to augment its analytical power.
With this unique complement of capabilities, Brain-
CODE is the first database of its kind in the world.
Brain-CODE is deployed at the High Performance Com-
puting Virtual Laboratory (HPCVL) data centre at
Queen’s University in Kingston, Ontario. The HPCVL is a
Compute Canada high-performance computing consor-
tium that supports regulatory-compliant (e.g., ICH E6, 21
CFR Part 11, HIPAA, PIPEDA) processes for securing
privacy of healthcare data [60]. All data are collected,
processed, maintained, and stored in Canada.
Online data/images can be accessed only on secure
websites via restricted portals requiring unique user-
names and passwords for each member of the study
team. User profiles are assigned only to study personnel
requiring access to enter/verify data, and credentials for
each user are vetted by the program manager.
Specific data-collection platforms with Brain-CODE
include:
1) Brain-CODE Subject Registry, a secure portal used
by study centres in Ontario to link encrypted
personal health information from study participants
to provincial health/administrative databases;
2) OpenClinica Enterprise, a regulatory-compliant,
web-based electronic data capture (EDC) system
and database for demographic and historical data,
diagnostic information, and clinician-rated assessments
and scales (OpenClinica, Waltham, MA, USA);
3) LimeSurvey e-PRO Questionnaires, an open-source
survey tool used by participants for direct entry of
the 20 self-reported measures using a laptop or
tablet while attending clinic visits (LimeSurvey,
Hamburg, Germany);
4) SPReD (originally the Stroke Patient Recovery
Research Database), a comprehensive online
repository powered by the open-source Extensible
Neuroimaging Archiving Toolkit (XNAT) imaging
informatics platform [61]. Structural and functional
MRI data are first converted to DICOM (Digital Im-
aging and Communications in Medicine) format at
each site prior to uploading [62], whereas EEG data
are uploaded as raw files for subsequent
standardization to 58 channels and conversion into a
universally readable format in EEGLAB. Supplementary
results, such as behavioural and physiological
data, and session notes, are uploaded through a
special sub-process. All files must be correctly
labeled in accordance with SPReD’s organizational
structure and naming conventions; an automated
pipeline scans for errors on a daily basis; and
5) BASE (BioArray Software Environment) and
LabKey, open-source laboratory-information
management systems that enable tracking and
management of proteomics and genomics
workflows, experiments, and raw data [63, 64].
Clinical data support is provided by Indoc Research for
OpenClinica and LimeSurvey, and by Rotman Research In-
stitute/Baycrest Health Sciences for SPReD. For clinical and
self-rated measures, source data verification is completed
using a remote, risk-based monitoring system that includes
centralized processes for cleaning and extracting data.
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Future CAN-BIND projects (see below) will use secure,
customizable Research Electronic Data Capture (REDCap)
tools for all clinical and self-reported data [65].
MRI data undergoes manual quality control (QC) pro-
cedures where trained raters check for visual artifacts
and then grade scans as usable or rejected; in the latter
case, rescanning is recommended if possible within the
study timeline. For fMRI data, preprocessing includes
conversion from DICOM to NIfTI (Neuroimaging
Informatics Technology Initiative) format [66] prior
to identifying the volume with the least motion, to
which the remaining volumes are registered.
Converted EEG data are resampled to 512 Hz with
channels re-referenced to Cz before digital filters are ap-
plied (high pass = 0.5 Hz, low pass = 100 Hz) and trigger
codes are standardized.
For a period following study closure, CAN-BIND data
are protected by OBI for the exclusive use of the investi-
gative team and its collaborators. However, in the future,
de-identified CAN-BIND data may be shared by OBI
with other collaborators and third parties for research
purposes. These datasets could be made available to
other clinical research teams with similar datasets for
comparison of treatment outcomes in other psychiatric
conditions (such as dementia, schizophrenia, and bipolar
disorder). Eligible third parties will be recognized re-
searchers or organizations who have submitted detailed
study plans and ethics boards approvals to the OBI. Be-
fore OBI discloses the de-identified data to any third
party, it will enter into an agreement with the latter to
protect confidentiality and ensure correct usage of data.
Analyses
We will examine several outcomes, including responders
at Week 8 who maintained response at Week 16, re-
sponders at Week 8 who are non-responders at Week
16, non-responders at Week 8 who respond at Week 16
with augmentation, and non-responders at Weeks 8 and
16, among other outcomes. A reasonably large dataset is
required to study adequately the complex clinical, neu-
roimaging, and molecular factors that contribute to
treatment outcomes. Our sample size target for this
phase of the CAN-BIND program is 200 patients and 90
healthy participants (290 in total).
To identify standalone features that differ significantly be-
tween responders and non-responders, either at baseline or
over the course of the study, parametric two-sample t-tests
will be used for features with normally distributed data.
Otherwise, the non-parametric Mann–Whitney U test will
be used. A significance threshold of α = 0.05 and multiple
testing corrections will be required. Given an input list of
up to 25,000 features, of which at least 250 are differentially
expressed between responders and non-responders, assum-
ing an overall false discovery rate of 5 %, and applying two-
sample t-testing procedures, a minimum of 49 subjects per
category are required for power of at least 90 % to correctly
identify a given feature which differs significantly between
the categories. If nonparametric testing procedures are
used, a minimum of 52 subjects per category are required
to achieve the same power. Target recruitment for patients
with MDD is 200. An estimated response rate of 60 %
would yield 120 responders and 80 non-responders. The
planned sample size is sufficiently powered for both para-
metric and non-parametric univariate testing. Multivariate
analysis and the development of prognostic signatures of
escitalopram response will follow univariate analysis.
Data analyses will be conducted using a suite of com-
mercial and open-source software tools installed on
high-end workstations at HPCVL. While data from each
analytical platform will be independently analyzed using
the methods described above, important relationships
(either correlational or causal) between modalities can
be detected through an integration of data collected
across assessment platforms for a given study subject.
To manage the integrated analyses of this complex data
set, we have established a Data Science Advisory Team
consisting of the Principal Investigators, domain-specific
experts (e.g., molecular or imaging team members), in-
formatics advisors, and operations support. This team will
oversee processes for data cleaning, preprocessing, inte-
gration, quality control and overall analytics plans for each
of the core research activities. Cross-domain as well as
domain-specific data interrogation will be conducted by
Working Groups responsible for applying specific analytic
approaches according to their expertise and contributing
to a master Statistical Analysis Plan. Conventional univari-
ate and multivariate statistical approaches will address
hypothesis-driven investigations, while a variety of analyt-
ics pipelines with both supervised and unsupervised tech-
niques will allow exploratory analyses. Machine-learning
approaches, including principle component analysis, ran-
dom forests, and support vector machines will be used to
identify subgroups of patients with shared symptoms and/
or biological features that could have clinical relevance.
Progress to date
Between 2013 and 2015, 159 participants (107 patients and
52 healthy participants) were screened and 134 (85 patients
and 49 healthy participants) entered at baseline in the ini-
tial protocol with the Emotional Face Categorization/Con-
flict Task during MRI and EEG sessions, as noted above.
Full neuroimaging data (to Week 8) were obtained from 71
patients and 45 healthy participants.
Table 3 lists the clinical characteristics of this first cohort
(N= 134) that were evaluable at baseline. Independent-
samples t-tests showed no significant demographic differ-
ences between patients and healthy participants. The pa-
tients were moderately depressed at baseline, as reflected
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by MADRS, QIDS-SR, and CGI-S mean scores, as well as
moderately impaired as assessed by psychosocial (SDS) and
work (LEAPS) functioning scales.
Discussion
The CAN-BIND study is a unique biomarker-discovery ini-
tiative in its mandate, scope, organizational structure, and
integrative approach. First, the study collects systematic
outcome data in the clinical, neuroimaging, and molecular
domains in an agnostic fashion, with no preconceived
identification of biomarkers for depression. Second, data
are aggregated and integrated using a secure informatics
platform that facilitates collaborative data sharing and
rigorous quality-control processes across sites. Third,
cross-domain and domain-specific analyses are undertaken
using high-dimensional mathematical models supple-
mented with conventional statistical tools.
While CAN-BIND-1 focuses on pharmacotherapy,
subsequent protocols will address biomarkers in treatment
response using other evidence-based interventions for
MDD, including transcranial magnetic stimulation, cogni-
tive behaviour therapy, cognitive remediation, and others.
Additional studies using CAN-BIND platforms to examine
integrated biomarkers involve youth at risk for serious
mental illness, suicide risk, and effects of childhood mal-
treatment on stress sensitivity and reward responsivity.
CAN-BIND also operates a dedicated reverse-translation
Table 3 Clinical characteristics of the first cohort (N = 134)
Characteristic Patients with
MDD (N = 85)
Healthy participants
(N= 49)
Female:Male, N (%) 50:35 (59 %:41 %) 32:17 (65 %:35 %)
Age in years, mean (SD), range 36.1 (12.5), 19–61 32.5 (10.2), 20–57
Ethnicitya, N (%)
Aboriginal 0 0
Arab 3 (4 %) 1 (2 %)
Asian 9 (11 %) 9 (18 %)
Black 1 (1 %) 0
Latin American/Hispanic 5 (6 %) 2 (4 %)
White 59 (69 %) 35 (71 %)
Other 5 (6 %) 2 (4 %)
Mixed 3 (4 %) 0
Marital status, N (%)
Never Married 48 (57 %) 26 (53 %)
Separated 7 (8 %) 1 (2 %)
Married 16 (19 %) 12 (25 %)
Divorced 7 (8 %) 3 (6 %)
Domestic Partnership 5 (6 %) 6 (12 %)
Widowed 2 (2 %) 1 (2 %)
Occupational status, N (%)
Working now 45 (53 %) 28 (57 %)
Disabled (permanent or
temporary)
13 (7 %) 0
Temporary leave 5 (3 %) 0
Looking, unemployed 10 (5 %) 3 (6 %)
Student 8 (4 %) 15 (31 %)
Retired 1 (1 %) 0
If employed, number of hours
scheduled to work over the past
2 weeks: mean (SD)
50.0 (27.2) 53.8 (25.8)
If employed, number of hours
missed due to symptoms over
the past 2 weeks: mean (SD)
10.5 (18.2) 0.1 (0.6)
Education, years: mean (SD) 14.1 (2.0) 15.9 (2.9)
Age of onset of MDD, years:
mean (SD), range 20.6 (10.7), 5–55 n/a
Single episode:Recurrent, N (%) 24:61 (29 %:71 %) n/a
No. previous episodes, mean (SD) 4.3 (2.8) n/a
Current episode duration
≤12 months 39 (46 %) n/a
1–2 years 13 (15 %)
>2 years 30 (35 %)
Unknown/not reported 3 (4 %)
Median duration (range), months 14.5 (3–151)
Comorbiditiesb,c
Substance-Related Disorders 7 (8 %) n/a
Table 3 Clinical characteristics of the first cohort (N = 134)
(Continued)
Anxiety Disorders 67 (79 %)
Eating Disorders 1 (1 %)
Stable medical conditions 52 (61 %)
Use of antidepressants during
current
episode, N (%) 60 (71 %) n/a
No. antidepressants used,
mean (SD)
1.7 (1.5)
Baseline MADRS, mean (SD) 29.9 (6.0) 0.4 (1.0)
Baseline YMRS, mean (SD) 2.2 (1.8) 0.3 (0.7)
Baseline CGI Severity, mean (SD) 4.7 (0.8) 1.0 (0.0)
Baseline QIDS-SR, mean (SD) 15.9 (4.3) 2.1 (1.7)
Baseline SDS, mean (SD) 16.6 (7.5) 0.0 (0.0)
Baseline LEAPS, mean (SD) 14.1 (6.1) 1.9 (2.7)
aCategories adapted from ethnic-origin groups listed in national census
questionnaires [67]
bBased on DSM-IV-TR, as determined by the Mini International
Neuropsychiatric Interview
cPercentages may not add up to 100 % because patients may have more than
1 comorbid condition
MDD Major depressive disorder, SD Standard deviation, MADRS Montgomery
Åsberg Depression Rating Scale, YMRS Young Mania Rating Scale, CGI Clinical
Global Impression, QIDS-SR Quick Inventory of Depressive Symptomatology,
Self-Report, SDS Sheehan Disability Scale, LEAPS Lam Employment Absence
and Productivity Scale
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platform with various pre-clinical groups that investigate
neuropharmacology of hedonic function in laboratory rats,
zebrafish high-throughput screening, electrophysiological
and behavioural impact of medications, and microRNA/in-
flammatory markers. CAN-BIND activities are broadly
disseminated through multimodal, iterative knowledge
translation/knowledge exchange initiatives that include
ongoing collaboration with patients, family members,
and other stakeholders in the community. Over time,
CAN-BIND will expand with new collaborations with
academic health centres, industry partners, and mental
health networks.
Conclusion
CAN-BIND is a large Canadian collaborative research
endeavor that is attempting to discover integrated clin-
ical, imaging and molecular biomarkers of treatment re-
sponse in MDD. It may also identify clinically relevant
subtypes of depression and further our knowledge of the
pathogenesis and pathophysiology of MDD. Given the
multifaceted study design, we also expect to find novel
psychobiological insights that will lead to the generation
of new hypotheses to be validated in future studies.
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